All In Biotech

Free tool

Drugs in development

Investigational drugs and biologics in industry-sponsored Phase 2 and Phase 3 trials that are active or finished in the last two years, and that FDA has not approved. Built from 10,322 ClinicalTrials.gov records, with code names and generic names merged. For approved drugs, use Drug Search.

Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations

Drugs in development

3,685

Not FDA-approved

In Phase 3

1,424

Highest phase reached

Matching your filters

98

Reset

98 drugs in development

Names, sponsors and conditions come from the trial records. Click a drug for its trials.

  • REGN4336Phase 22 trials

    Regeneron · Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)

  • vudalimabPhase 22 trials

    Xencor, Inc. · Ovarian Cancer, Clear Cell Carcinoma, Endometrial Cancer

  • ZalifrelimabPhase 22 trials

    ImmunoGenesis · Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer

  • ZEN003694ZEN-3694Phase 22 trials

    Zenith Epigenetics · mCRPC, Metastatic Castration-Resistant Prostate Cancer

  • ACE-86225106Phase 21 trial

    Acerand Therapeutics (Shanghai) Limited · Solid Tumor, Adult, BRCA1 Mutation, BRCA2 Mutation

  • ADI-212Phase 21 trial

    Adicet Therapeutics · Prostate Cancer Metastatic

  • AMO959BY1298, BY101298Phase 21 trial

    Novartis · PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy

  • AMXI-5001Phase 21 trial

    AtlasMedx, Incorporated · Advanced Malignant Neoplasm, Breast Cancer, Ovarian Cancer

  • AS1986NSPhase 21 trial

    Antelope Surgical Solutions, Inc · Prostate Cancer, Prostate Cancer (Adenocarcinoma), Fluorescence Imaging

  • ASP5541PRL-02Phase 21 trial

    Astellas · Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer

  • AZD0516Phase 21 trial

    AstraZeneca · Metastatic Prostate Cancer

  • AZD0754Phase 21 trial

    AstraZeneca · Metastatic Prostate Cancer

  • AZD6621Phase 21 trial

    AstraZeneca · Prostate Cancer

  • AZD8359Phase 21 trial

    AstraZeneca · Metastatic Prostate Cancer

  • AZD9750Phase 21 trial

    AstraZeneca · Prostate Cancer

  • CC-38Phase 21 trial

    CuraCell TX AB · Metastatic Colorectal Cancer, Prostate Cancer Metastatic, Prostate Cancer Locally Advanced

  • CRG-150Phase 21 trial

    CoRegen, Inc. · HR-positive, HER2-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Prostate Cancer

  • Debio 4228Phase 21 trial

    Debiopharm International SA · Prostate Cancer

  • ETX-19477Phase 21 trial

    858 Therapeutics, Inc. · Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer

  • FG-3246FOR46Phase 21 trial

    Kyntra Bio · Metastatic Castration-Resistant Prostate Cancer

  • FOG-001Phase 21 trial

    Parabilis Medicines, Inc. · Cancer, Colorectal Cancer, Solid Tumor

  • Ga-68-NGULPhase 21 trial

    Cellbion Co., Ltd. · Prostate Cancer, mCRPC

  • GDC-1261Phase 21 trial

    Roche (Genentech) · Advanced Prostate Cancer, Metastatic Prostate Cancer

  • GVV858Phase 21 trial

    Novartis · Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer

  • HP518Phase 21 trial

    Hinova Pharmaceuticals Inc. · Metastatic Castration-resistant Prostate Cancer

  • HRS-1738Phase 21 trial

    Jiangsu HengRui Medicine Co., Ltd. · PET Imaging in Patients With Prostate Cancer

  • INV-9956Phase 21 trial

    Shenzhen Ionova Life Sciences Co., Ltd. · Advanced Metastatic Castration Resistant Prostate Cancer

  • KVA12123Phase 21 trial

    Kineta Inc. · Cancer, Solid Tumor, Melanoma

  • Lu-177-DGULPhase 21 trial

    Cellbion Co., Ltd. · Prostate Cancer, mCRPC

  • MHB048CPhase 21 trial

    Minghui Pharmaceutical (Hangzhou) Ltd · mCRPC (Metastatic Castration-resistant Prostate Cancer), Advanced Malignant Solid Tumor

  • NUV-1511Phase 21 trial

    Nuvation Bio Inc. · Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC)

  • TransThera Sciences (Nanjing), Inc. · Prostate Cancer (CRPC)

  • REGN15505Phase 21 trial

    Regeneron · Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)

  • REGN21353Phase 21 trial

    Regeneron · Metastatic Castration-Resistant Prostate Cancer, mCRPC

  • RS-113Phase 21 trial

    R-Pharm International, LLC · Metastatic Castration-resistant Prostate Cancer

  • RV001VPhase 21 trial

    RhoVac APS · Prostate Cancer Recurrent

  • RYZ711Phase 21 trial

    RayzeBio, Inc. · Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate, Metastatic Castration-resistant Prostate Cancer (mCRPC)

  • TransThera Sciences (Nanjing), Inc. · Prostate Cancer (CRPC)

  • SHR-4394Phase 21 trial

    Jiangsu HengRui Medicine Co., Ltd. · Prostate Cancer

  • SHR3680Phase 21 trial

    Jiangsu HengRui Medicine Co., Ltd. · Prostate Cancer

  • SNS-101anti-VISTAPhase 21 trial

    Sensei Biotherapeutics, Inc. · Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer

  • ST101Phase 21 trial

    Sapience Therapeutics · Glioblastoma, Melanoma Stage IV, Breast Cancer

  • SV-102Phase 21 trial

    Syncromune, Inc. · Metastatic Castration-resistant Prostate Cancer

  • SX-682Phase 21 trial

    Syntrix Biosystems, Inc. · Metastatic Castration-resistant Prostate Cancer

  • TB511Phase 21 trial

    Twinpig Biolab, Inc. · NSCLC, Prostate Cancer, Colorectal Cancer

  • TQB3201Phase 21 trial

    Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Metastatic Castration-resistant Prostate Cancer

  • TT-10Phase 21 trial

    Portage Biotech · Renal Cell Cancer, Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer

  • TY-302Phase 21 trial

    TYK Medicines, Inc · Metastatic Castration-resistant Prostate Cancer (mCRPC)

NewerPage 2 of 2

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.